Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24800091 | 1.00 | IRAK4 (1.00) | IRAK4MAP3K7 | |
| SCHEMBL30046066 | 1.00 | IRAK4 (1.00) | IRAK4MAP3K7 | |
| SCHEMBL30150298 | 0.94 | IRAK4 (1.00) | IRAK4MAP3K7 | |
| SCHEMBL24799607 | 0.94 | IRAK4 (1.00) | IRAK4MAP3K7 | |
| SCHEMBL19742916 | 0.94 | IRAK4 (1.00) | IRAK4MAP3K7 | |
| SCHEMBL19742913 | 0.94 | IRAK4 (1.00) | IRAK4MAP3K7 | |
| SCHEMBL30044995 | 0.94 | IRAK4 (1.00) | IRAK4MAP3K7 | |
| SCHEMBL24799802 | 0.94 | IRAK4 (1.00) | IRAK4MAP3K7 | |
| SCHEMBL22452428 | 0.94 | IRAK4 (1.00) | IRAK4MAP3K7 | |
| SCHEMBL24799799 | 0.93 | IRAK4 (1.00) | IRAK4MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230095835-A1 | 2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2023-03-30 | — | — | US | claimed |
| EP-3475263-B1 | 2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-12-28 | — | — | EP | claimed |
| US-10710983-B2 | 2,4-diamino-pyrimidine compounds and method for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | claimed |
| US-20170369476-A1 | 2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2017-12-28 | — | — | US | claimed |
| US-20230095835-A1 | 2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2023-03-30 | — | — | US | disclosed |
| EP-3475263-B1 | 2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-12-28 | — | — | EP | disclosed |
| EP-3475263-B1 | 2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-12-28 | — | — | EP | disclosed |
| US-11524955-B2 | 2,4-diamino-pyrimidine compounds and method for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-11524955-B2 | 2,4-diamino-pyrimidine compounds and method for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20200299276-A1 | 2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-20200299276-A1 | 2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-10710983-B2 | 2,4-diamino-pyrimidine compounds and method for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10710983-B2 | 2,4-diamino-pyrimidine compounds and method for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20170369476-A1 | 2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| US-20170369476-A1 | 2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230095835-A1 | 2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | IRAK4, IRAK1, IRAK3 | IRAK4 1/4885MAP3K7 30/4885 |
| US-11524955-B2 | 2,4-diamino-pyrimidine compounds and method for making and using the compounds | IRAK4, IRAK1, IRAK3 | IRAK4 1/4885MAP3K7 30/4885 |
| US-20170369476-A1 | 2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885MAP3K7 33/4885 |
| US-10710983-B2 | 2,4-diamino-pyrimidine compounds and method for making and using the compounds | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885MAP3K7 33/4885 |
| US-20200299276-A1 | 2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | IRAK4, IRAK1, IRAK3 | IRAK4 1/4885MAP3K7 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.